Flagship Pioneering, LLC
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Flagship Pioneering, LLC reported 6 stock positions worth $591.9 million. Its top holding was Moderna (MRNA) at 52.3% of the portfolio, followed by Foghorn Therapeutics (FHTX, 19.9%) and Sana Biotechnology (SANA, 17.6%). Its holdings were unchanged from Q2 2024.
- Most Recent 13F
- Q2 2026
- Location
- CAMBRIDGE, MA
- CIK
- 0001400240
- Portfolio Value
- $591.9M (Q3 2024)
- SEC Filing
- 0000950123-24-011756 ↗ filed Nov 14, 2024
Holdings Value
Holdings 6 stocks · $591.9M
| MRNA Moderna Inc. | 52.30% | 4,632,149 | $309.6M | No change |
| FHTX Foghorn Therapeutics Inc. | 19.94% | 12,674,120 | $118.0M | No change |
| SANA Sana Biotechnology Inc. | 17.57% | 25,001,856 | $104.0M | No change |
| OMGAQ Omega Therapeutics Inc. | 6.02% | 29,225,579 | $35.7M | No change |
| MCRB Seres Therapeutics Inc. | 3.70% | 23,117,045 | $21.9M | No change |
| SYRS Syros Pharmaceuticals Inc. | 0.47% | 1,293,849 | $2.8M | No change |
Portfolio Sells Q2 2024 → Q3 2024
| None this quarter. | |||
Portfolio Buys Q2 2024 → Q3 2024
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 5 | $1.5B | GENB, MRNA, SANA, FHTX, MCRB |
| Q1 2026 | 5 | $1.2B | GENB, MRNA, SANA, FHTX, MCRB |
| Q4 2025 | 4 | $324.0M | MRNA, SANA, FHTX, MCRB |
| Q3 2025 | 4 | $292.6M | MRNA, SANA, FHTX, MCRB |
| Q2 2025 | 4 | $268.5M | MRNA, SANA, FHTX, MCRB |
| Q1 2025 | 4 | $235.8M | MRNA, FHTX, SANA, MCRB |
| Q4 2024 | 5 | $334.2M | MRNA, FHTX, SANA, OMGAQ, MCRB |
| Q3 2024 | 6 | $591.9M | MRNA, FHTX, SANA, OMGAQ, MCRB |
| Q2 2024 | 6 | $843.4M | MRNA, SANA, FHTX, OMGAQ, MCRB |
| Q1 2024 | 7 | $1.5B | MRNA, SANA, OMGAQ, FHTX, DNLI |